Until now, the strategies for treating this tumor were aimed at attacking the tumor cells and had little success. The latest studies indicate that trying to destroy what surrounds the tumor is possibly a better strategy…
Trebananib (formally known as AMG 386; Amgen) is a first-in-class peptide-Fc fusion protein (or peptibody) that targets angiogenesis (the growth of new blood vessels into cancerous tumors) by inhibiting the binding of both angiopoietin 1 and 2 to the Tie2 receptor. This is very different mechanism of action than other agents that also effect angiogenesis by inhibiting vascular endothelial growth factor (VEGF) such as bevacizumab (Avastin; Genentech). Trebananib does not increase the risks of hypertension (high blood pressure) and bowel perforation like bevaciuzmab, but still has a similar impact on tumor shrinkage and delaying cancer progression…
HPV testing is not reimbursed by SHI funds In screening for cervical cancer, the German statutory health insurance (SHI) funds currently offer an annual cytologic examination of mucosal cells from a smear taken from the neck of the womb (cervix). This test is called a Pap smear. Since it became known that infection with HPV is the main risk factor for developing cervical cancer, experts have been discussing whether HPV testing is also a suitable screening method or is even superior to a cytologic test…
Glioblastoma is the most common and lethal brain cancer. Current standard treatments include surgical resection, adjuvant chemotherapy and radiotherapy. …
source : http://www.sciencedaily.com/releases/2014/07/140722102249.htm
source : http://www.sciencedaily.com/releases/2014/07/140710111900.htm
source : http://www.sciencedaily.com/releases/2014/06/140624110720.htm
source : http://www.sciencedaily.com/releases/2014/06/140611102207.htm
source : http://www.sciencedaily.com/releases/2014/05/140529100721.htm
source : http://www.sciencedaily.com/releases/2014/05/140526101656.htm